Citius Pharmaceuticals Regains Nasdaq Compliance

Citius Pharmaceuticals ( (CTXR) ) just unveiled an update.

On July 8, 2025, Citius Pharmaceuticals announced that it had regained compliance with Nasdaq’s minimum bid price requirement, as its stock maintained a closing bid price of $1.00 or greater for 10 consecutive trading days. This compliance ensures that Citius Pharma’s securities will continue to be listed and traded on the Nasdaq Stock Market, reflecting the company’s commitment to delivering critical care products and creating long-term value for shareholders.

The most recent analyst rating on (CTXR) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.

Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of first-in-class critical care products. The company has a pipeline that includes LYMPHIR, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma, Mino-Lok®, an antibiotic lock solution, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief.

Average Trading Volume: 2,519,816

Technical Sentiment Signal: Sell

Current Market Cap: $23.52M

For an in-depth examination of CTXR stock, go to TipRanks’ Overview page.